Mechanism of PARP inhibitor resistance and potential overcoming strategies

PARP inhibitors (PARPi) are a kind of cancer therapy that targets poly (ADP-ribose) polymerase. PARPi is the first clinically approved drug to exert synthetic lethality by obstructing the DNA single-strand break repair process. Despite the significant therapeutic effect in patients with homologous r...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Xiaoyu, Li, Ping, Zhou, Qi, He, Ruyuan, Wang, Guannan, Zhu, Shiya, Bagheri, Amir, Kupfer, Gary, Pei, Huadong, Li, Juanjuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425807/
https://www.ncbi.nlm.nih.gov/pubmed/37588193
http://dx.doi.org/10.1016/j.gendis.2023.02.014

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425807/
https://www.ncbi.nlm.nih.gov/pubmed/37588193
http://dx.doi.org/10.1016/j.gendis.2023.02.014

Ejemplares similares